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Nitrofurantoin and fosfomycin for 
resistant urinary tract infections:  
old drugs for emerging problems
SUMMARY
Uncomplicated urinary tract infection is one of the most common indications for antibiotic use in 
the community. However, the Gram-negative organisms that can cause the infection are becoming 
more resistant to antibiotics.
Many multidrug resistant organisms retain susceptibility to two old antibiotics, nitrofurantoin 
and fosfomycin. Advantages over newer drugs include their high urinary concentrations and 
minimal toxicity.
Fosfomycin is a potential treatment option for patients with uncomplicated urinary tract infection 
due to resistant organisms. Nitrofurantoin may be more effective and can be used for urinary 
infections in pregnant women.
Nitrofurantoin
Nitrofurantoin has been available since 1953, and 
in Australia since the 1970s. Its exact mechanism 
of action is not well understood and presumably 
multifactorial. Nitrofurantoin requires reduction 
by bacterial enzymes producing ‘highly reactive 
electrophilic’ metabolites. These then inhibit 
protein synthesis by interfering with bacterial 
ribosomal proteins.11
Nitrofurantoin has 80% oral bioavailability, and 
approximately 25% is excreted unchanged in the 
urine, with only a small portion reaching the colon.12 
Like fosfomycin, therapeutic concentrations are 
only reached in the urinary tract,13 so the clinical 
use of nitrofurantoin is limited to the treatment 
of uncomplicated urinary tract infection in 
women. Administration with food results in higher 
urinary concentrations and fewer gastrointestinal 
adverse effects.
Antimicrobial activity
Nitrofurantoin is active against common causes of 
urinary tract infection including E. coli, Citrobacter 
and Enterococcus. Klebsiella and Enterobacter are 
less reliably susceptible. Serratia, Acinetobacter, 
Morganella, Proteus and Pseudomonas are usually 
resistant.14 Overall, resistance to nitrofurantoin 
is uncommon and many multidrug resistant 
organisms retain susceptibility.15-17 Australian data 
are limited, but studies suggest resistance rates in 
E. coli of 1–2%.4,6
Introduction
Antimicrobial resistance is increasing worldwide, 
resulting in infections that are more difficult to treat 
and associated with higher mortality, morbidity 
and cost.1-3 In Australia, multidrug resistant 
Gram-negative bacilli are responsible for a rising 
proportion of community-acquired uncomplicated 
urinary tract infections. Consequently, empiric 
therapy is more likely to fail. This has resulted in 
increasing numbers of patients with uncomplicated 
urinary tract infections requiring hospitalisation for 
intravenous antibiotics because there are no oral 
treatment options.
Limited Australian data are available for 
antimicrobial resistance rates in community-onset 
urinary tract infections.4,5 One large national survey 
of urinary isolates from 2015 found resistance rates 
in Escherichia coli of 43% for ampicillin, 9% for 
amoxicillin with clavulanic acid, 16% for cefazolin, 
22% for trimethoprim, and 7% for ciprofloxacin.6 
It is likely that resistance rates have continued to 
rise since then.
There are few new antibiotics on the horizon and 
those that have been recently approved are mostly 
for intravenous use, so older ‘forgotten’ drugs are 
being re-explored for the treatment of cystitis.7-10 
Nitrofurantoin and fosfomycin are old antibiotics. 
They share some important properties including high 
concentrations in the urinary tract, a minimal impact 
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Efficacy and safety
A meta-analysis of 27 older controlled trials 
(4807 patients) found clinical cure rates of 79–92%, 
similar to comparator antibiotics. Only mild toxicities 
(most commonly gastrointestinal) and no cases 
of pulmonary fibrosis or hepatotoxicity were 
reported.18 Dosing recommendations for the standard 
formulation are 50–100 mg four times daily. There 
is a long-acting formulation available overseas, but 
not in Australia, which can be dosed twice daily. 
This slow-release formulation (100 mg three times 
daily) was used in a recent open-label comparison 
with fosfomycin. The cure rate was 70% in the 
nitrofurantoin group.19
Historically nitrofurantoin was thought to be 
contraindicated if the creatinine clearance was 
less than 60 mL/minute due to an increased risk 
of toxicity. However, recommendations have been 
changing to allow cautious, short-term use in patients 
with mild renal impairment (30–60 mL/min) if there 
are no alternative antibiotics.20,21 Nitrofurantoin can 
be used to treat cystitis in pregnancy (although 
not beyond 38 weeks gestation due to the risk of 
haemolytic anaemia in the neonate).
Nitrofurantoin became a preferred drug in the 
international consensus guidelines for urinary tract 
infection in 2010.22 These emphasised the lower rates 
of ‘collateral damage’ on gastrointestinal flora.23-24 
Table    Features of nitrofurantoin and fosfomycin
Characteristic Nitrofurantoin Fosfomycin
Year of discovery 1953 1969
Formulations Nitrofurantoin macrocrystal
50 mg, 100 mg capsules
Slow-release formulation not available in Australia
Older microcrystal formulation less available now (more adverse effects)
Fosfomycin trometamol
3 g sachet containing granules to be dissolved in 
water
Intravenous formulation available but for 
specialised use only
Pharmacokinetics High urinary concentrations
Serum concentrations negligible
Long half-life with high urinary concentrations
Serum concentrations inadequate for treatment of 
systemic infection
Mechanism of action Not well understood, multifactorial, inhibits ribosomal protein 
synthesis
Inhibits pyruvyl transferase and therefore cell wall 
synthesis
Spectrum of activity Mostly susceptible: E. coli, Enterococcus
Variably susceptible: Klebsiella, Enterobacter, Citrobacter 
and Providencia
Typically resistant: Proteus, Serratia, Acinetobacter, Morganella 
and Pseudomonas
Mostly susceptible: E. coli
Variably susceptible: Klebsiella, Proteus, Citrobacter, 
Enterobacter, Pseudomonas and Enterococcus
Typically resistant: Morganella and Acinetobacter
Resistance Uncommon Uncommon
Indications Uncomplicated urinary tract infection in women Uncomplicated urinary tract infection in women
Dosing 50–100 mg 4 times a day for 5 days Single 3 g oral dose
Adverse events Infrequent, mainly gastrointestinal
Rare reports of pulmonary or liver toxicity, peripheral neuropathy




Category A, although not recommended beyond 38 weeks gestation 
due to risk of haemolytic anaemia in neonates. For this reason it is 
also best to avoid during the first month of breastfeeding
Category B2, small amounts excreted in breast milk 
so not recommended in breastfeeding
Children Avoid <1 month of age Avoid <12 years of age
Interactions Few significant drug interactions Co-administration with metoclopramide can lower 
serum and urine concentrations
Renal impairment Contraindicated if CrCl <30 mL/min
Cautious use between CrCl 30–60 mL/min if benefits outweigh risks
Dose reduction required if CrCl <50 mL/min
CrCl   creatinine clearance
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Nitrofurantoin and fosfomycin for resistant urinary tract infections
It remains to be seen if resistance rates increase 
as a consequence of this recommendation and the 
subsequent rise in nitrofurantoin prescribing. The 
true incidence of major hepatic and pulmonary 
toxicity is unclear, but this appears to be more 
common with long-term use in the elderly.14 For 
the short-term treatment of uncomplicated urinary 
tract infection in otherwise healthy young women, 
nitrofurantoin is a safe and effective choice, and 
overall efficacy and rates of adverse events appear 
similar to comparator antibiotics. In patients with 
infections due to multidrug resistant organisms and 
therefore few alternative treatment options, we 
recommend using 100 mg four times daily for five 
days, administered with food to optimise absorption 
and efficacy.
Fosfomycin
Fosfomycin was first isolated in Spain in 1969, and 
was introduced in Europe throughout the 1970s.25 
It is a small molecule from a unique drug class that 
acts by inhibiting pyruvyl transferase. This enzyme 
is responsible for synthesising the precursors of 
peptidoglycan, the key component of the bacterial 
cell wall. Uptake in the USA was initially limited due 
to problems with susceptibility testing, but this was 
standardised in 1983.
Fosfomycin trometamol, an oral formulation that 
can be taken as a single 3 g dose, was introduced in 
1995. In many countries it is now a first-line treatment 
option for uncomplicated urinary tract infection in 
women.22 This single-dose regimen is attractive due 
to better adherence and is generally well tolerated. 
While transient gastrointestinal disturbance can occur, 
serious adverse events are rare.26
In Australia, fosfomycin was only previously available 
via the Special Access Scheme. The Therapeutic 
Goods Administration has now approved it for acute 
uncomplicated lower urinary tract infection, in females 
more than 12 years of age, caused by susceptible 
organisms (Enterobacteriaceae including E. coli, and 
Enterococcus faecalis).
Antimicrobial activity
Susceptibility testing for fosfomycin is available, but 
can be complicated and is not necessarily routine in 
Australian microbiology laboratories. Fosfomycin is 
most active against E. coli, and minimum inhibitory 
concentrations are typically low.27-29 Other urinary 
pathogens such as Klebsiella, Proteus, Citrobacter, 
Enterobacter, Pseudomonas and Enterococcus have 
variable susceptibility.30-32 Morganella morganii 
and Acinetobacter are typically resistant.28 Urinary 
concentrations following a single 3 g dose are 
generally sufficient to treat patients infected with 
susceptible organisms, although some recent data 
suggest more variability in urinary concentrations 
than previously thought.33,34
As fosfomycin has a unique structure there is minimal 
cross-resistance with other antibiotics. At present, 
many multidrug resistant isolates remain susceptible 
to fosfomycin, even in geographic regions where 
there has been widespread use of the drug.35,36 
No comprehensive studies examining fosfomycin 
susceptibility have been conducted in Australia.
While resistant subpopulations of bacteria may 
develop with fosfomycin exposure, resistant strains 
do not seem to easily survive in vivo.32,37-40 However, 
there are multiple resistance mechanisms and there 
are reports of increasing resistance correlating with 
higher fosfomycin usage in Spain.32,41-43 Plasmid-
mediated resistance, which could disseminate more 
readily, has been described in Japan,44 and among 
livestock45 and pets46 in China.
Efficacy and safety
Historically, the clinical efficacy of fosfomycin 
was thought to be similar to antibiotics such as 
trimethoprim, trimethoprim/sulfamethoxazole, 
fluoroquinolones, beta-lactams and nitrofurantoin, 
with reported cure rates of 75–90%.47-51 However, 
methodological flaws in the older studies may have 
resulted in clinical efficacy being overestimated. 
A recent large randomised trial found a lower 
clinical cure rate with fosfomycin compared with 
nitrofurantoin (58% vs 70%, p=0.004).19 While some 
recent observational studies have demonstrated 
fosfomycin efficacy in uncomplicated urinary tract 
infection caused by resistant organisms,52-56 including 
non-inferiority to carbapenems,57,58 there are reports 
of treatment failures particularly with Klebsiella.59
As low serum concentrations lead to treatment 
failures, fosfomycin is not appropriate for patients with 
bacteraemia or upper urinary tract infections such as 
pyelonephritis. Occasionally, longer courses have been 
used to treat complicated urinary tract infection, for 
example as completion therapy when there are no 
oral alternatives to intravenous antibiotics.57 There is 
also an emerging role in prostatitis and perioperative 
prophylaxis for urological procedures in men.60-62 
Specialist infectious diseases input should be sought 
for these complex cases if off-label use or prolonged 
courses of therapy are being considered.
Fosfomycin is generally well tolerated, with adverse 
events rare and usually transient. Gastrointestinal events 
(9% diarrhoea, 4% nausea) have been most commonly 
reported with rare reports of other more serious 
problems.26 Co-administration with metoclopramide 
can lower serum and urinary concentrations and should 
be avoided, but there are few other problematic drug 
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interactions. Fosfomycin is classified in pregnancy 
category B2. It is not recommended in breastfeeding as 
small amounts are excreted in breast milk. Given there 
are minimal data on use in children under 12 years of 
age, it is not advised for this group.
In Australia, we currently recommend reserving 
fosfomycin for the treatment of uncomplicated urinary 
tract infection in patients when the standard first-line 
drugs are not an option. Part of the rationale behind 
this is to minimise the emergence of resistance and 
prolong the usefulness of fosfomycin for patients 
without alternative options.35 As resistance to other 
drugs inevitably rises and local experience increases, 
fosfomycin may become a first-line option in the future.
Antibiotic resistance
While re-exploring older ‘forgotten’ drugs like 
nitrofurantoin and fosfomycin is a useful strategy, it 
represents only part of the multifaceted response 
required to tackle the complex problem of 
antimicrobial resistance and ‘preserve the miracle’ 
of antimicrobials over the coming decades.63 As 
we have seen historically with virtually all other 
antibiotics, resistance is likely to emerge as usage 
increases. It remains to be seen how long this will 
take, to what extent it will occur and whether it 
will be via dissemination of existing resistance 
mechanisms or evolution of new ones. The increasing 
failure of standard empirical therapy for urinary tract 
infection is foreseeable, and it is likely that more 
patients will require microbiological testing before 
starting antibiotics, not only for individualised patient 
management but also for broader epidemiological 
surveillance to inform guideline recommendations.
Consultation with an infectious diseases specialist 
can assist with the management of patients with 
multidrug resistant infections and leads to better 
outcomes.64 Other important strategies include 
the development of new antimicrobial drugs, 
preserving those currently available by judicious 
use, implementation of comprehensive antimicrobial 
stewardship programs and stringent infection 
control practices worldwide to reduce the spread of 
resistant organisms.
Conclusion
Nitrofurantoin is suitable for uncomplicated 
lower urinary tract infections. Bacterial resistance 
is uncommon.
Fosfomycin is a safe and effective antibacterial 
drug for urinary tract infections, but its use should 
be limited to delay the development of resistance. 
It will prove to be a useful treatment option for 
community-based treatment of patients with 
resistant organisms. 
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